Stoke Therapeutics and Biogen Present Zorevunersen Data at EEC
ATHENS, Greece, September 1, 2026 Stoke Therapeutics and Biogen announced presentations of clinical data supporting the potential of zorevunersen,...
Disease-Modifying Therapy
Advertisement
Eisai Advances Alzheimer’s Care with LEQEMBI IQLIK Approval
TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...
Larimar’s Nomlabofusp Shows Long-Term Promise in Friedreich’s Ataxia
Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of...
FDA Approves LEQEMBI IQLIK Subcutaneous Autoinjector for Maintenance Dosing in Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...
Advertisement
